1. Prospective partnerships for industry and academia Emily Gale Medical Research Council 21 November 2013

2. Encourage and support high-quality research with the aim of improving human health. Produce skilled researchers. Advance and disseminate knowledge and technology to improve the quality of life and economic competitiveness in the UK and worldwide. Promote dialogue with the public about medical research. MRC mission

3. Encourage and support high-quality research with the aim of improving human health. Produce skilled researchers. Advance and disseminate knowledge and technology to improve the quality of life and economic competitiveness in the UK and worldwide. Promote dialogue with the public about medical research. Work with industry to drive economic development Post-Comprehensive Spending Review

4. Rickets caused by lack of vitamin D (1916) Discovery and development of penicillin (1940s) Pioneered randomised controlled trial design (1940s) Discovery of link between smoking and cancer (1950s) Clinical trials for radiotherapy for cancer (1960s) Clinical trials of chemotherapy for leukaemia (1970s) Invention of DNA fingerprinting (1980s) Gene for Huntington’s disease discovered (1990s) Humanised therapeutic antibodies in widespread use (2000s) MRC discoveries and developments

5. MRC investment in research, 2012/13 MRC research expenditure - £766.9 million in 12/13 £343.1m for more than 400 programmes in MRC research units and institutes. £334.6m on 1,400 grants to researchers in universities, medical schools and research institutes. £71.3m on training and career development. £54.2m on individual grants with industry partners £29.5m on industry/academic consortia

6. MRC resources available to researchers from industry and academia MRC research underpins R&D –Patient Research Cohorts Initiative –UK Biobank –UK Brain Bank Network –WT/MRC Stem Cell Centre –Developing animal models –FARR Institute –Clinical trials and methodology resources MRC engagement directly with industry

7. Discovery and exploratory researchApplication and delivery research MRC leadNIHR lead Pharmacogenomics Animal/human models Regenerative medicine Genetics/genomics Structural biology Imaging Systems medicine Global health Ageing: life course Stem cells Infections Population science Experimental medicine Methodology Global health Stratified medicine Public health E-health HTA Trials EME Trials (Late stage III) Programmes in Applied research Research for Patient Benefit Invention for Innovation Service Delivery and Organisation CSO (Scotland) WORD (Wales) HSCNI (Northern Ireland) Current focuses of MRC activity

8. Where industry and MRC academics meet 92 new products and interventions launched onto the market. Creation or growth of 104 companies, 56 formed since 2006. 578 patents granted or published since 2006, with around 30% licensed. More than 100 new industry collaborations are reported every year outside of the MRC-mediated collaborations. Cross-sector MRC funded partnerships

9. Types of products and interventions generated by MRC-supported scientists

10. MICA – a gateway to funding Encouraging and supporting collaborative research projects between academic and industry researchers. Key feature: Flexibility –Level and nature of industry contribution can vary –Companies of any size can participate –Applies to all MRC funding and fellowship schemes Agreement between partners forms part of application. >80 awards so far, including collaboration involving: –38 different HEI –50 different industry partners

11. MICA: “More than just money” MenBioVax: meningitis vaccine developed by ImmBio with TSB funding following a collaborative programme with Bristol Medical School MRC DPFS funding to take MenBioVax through preclinical studies “There aren’t many other sources of funding for this type of project in the UK. It brings more than just money, of course. It’s important for potential investors to be able to see that bodies like the MRC have confidence in our technology and products.” Graham Clarke, ImmBio CEO

12. MICA: “A very positive experience” Evaluation of a potential biomarker for idiopathic pulmonary fibrosis. Collaboration between scientists at University of Nottingham, GlaxoSmithKline and Queen Mary, University of London “We all believe in the target but each of us has only one piece of the jigsaw.” “MICA is a tremendous initiative that will accelerate the development of new drugs to meet clinical needs.” Dr Andy Blanchard Director of External Discovery, GSK

13. MICA numbers on the rise

14. MRC working with industry MRC engages directly with industry –DSTT –MRC/ABPI Inflammation and Immunology Initiative –Stratified Medicines Innovation Platform MRC promotes partnerships and translational science –MRC/AZ Mechanisms of disease –Confidence in Concept –DPFS/DCS –BMC – Biomedical Catalyst –Bioinformatics call –Experimental Medicine Challenge Grants PPP in Europe

15. Inflammation and Immunology Initiative A new way of funding from the MRC Collaboration with ABPI:  Disease-focused workshops COPD Rheumatoid arthritis  Brought together experts from academia and industry  Identified research priorities  Ear-marked funds for research consortiums to address barriers and exploit opportunities  MRC invested £9.5m over four years

16. Stratified Medicine Consortia Disease-focused cross-sector consortia Pitzalis Gaucher’s disease Hepatitis C Psoriasis Schizophrenia Primary Biliary Cirrosis  MRC invested £50m over four years  Exploiting existing expertise and clinical research infrastructure Aim to provide a dynamic platform for disease focused research

17. RA Partners

18. MRC working with industry MRC engages directly with industry –DSTT –MRC/ABPI Inflammation and Immunology Initiative –Stratified Medicines Innovation Platform MRC promotes partnerships and translational science –MRC/AZ Mechanisms of disease –Confidence in Concept –DPFS/DCS –BMC – Biomedical Catalyst –Experimental Medicine Challenge Grants PPP in Europe

19. Products and interventions by pipeline stage Initial development Refinement, Non-clinical Refinement, Clinical Early clinical assessment Late clinical evaluation Market authorisation Small-scale adoption Wide-scale adoption

20. “Investable opportunities” Over 600 projects developing new products or interventions - at all stages of development have been reported 110 have reached the market since 2006 For the first time we can track all of these, noting which are active, closed, seeking support, and which are progressing 75% of projects are prior to the “valley of death”, 25% after Around 80 would benefit from further investment – so could be “investable opportunities” The first year in which we published this data (2011) the three hundred development projects were used by the science minister as an example of the untapped potential that the biomedical catalyst could unlock “Valley of death”

21.  To provide European citizens with timely access to new and effective diagnostics and treatments that improve their health and wellbeing  Helping safeguard the future international competitiveness of the European biopharmaceutical industry and secure growth and jobs. General Objectives of IMI 2

22. The European Union and the pharmaceutical industry have joined forces to make drug R&D processes in Europe more innovative and efficient, enhance Europe’s competitiveness & address key societal challenges by forming the biggest PPP in Life Science 22 Innovative Medicines Initiative: Joining forces in the healthcare sector

23. COMBACTE CLIN-Network 280 members and Candidate members

24. 22 million euros awarded to UK SMEs

25. 1 in 4 UK SME applicants are successful in IMI

26. Thinking about cross-sector collaboration Bioinformatics Computer science Data management Diagnostics Engineering Microscopy/scanning Clinical biology

27. Thank you for your attention Emily Gale emily.gale@headoffice.mrc.ac.uk

28. What is it? Turning discoveries into clinical benefits, while maintaining the basic research that drives it. The MRC’s translational strategy: –builds on the MRC’s existing role in pushing forward basic knowledge to improve people’s health and wealth –strengthens the support and oversight of the translational processes Basic medical research Prototype discovery and design Pre-clinical development Early clinical trials Late clinical trials Translation

29. Translation of basic research takes time 1973Mouse antibodies isolated by César Milstein and George Köhler (MRC Laboratory of Molecular Biology) 1986Michael Neuberger and Sir Greg Winter ‘humanise’ mouse antibodies Sir Greg develops and patents technology for producing antibodies in vitro 2003 MRC-developed Humira ® licensed to treat UK arthritis patients 200821 monoclonal antibody drugs on market for treating breast cancer, leukaemia, asthma, arthritis, psoriasis and transplant rejection 2011Antibodies make up 1/3 of new drugs for cancer, arthritis and asthma; global antibody market estimated to be worth $40bn

30. MRC spend by research activity, 2010/11

31. MRC spend by health category, 2010/11